Leslie Chong appointed Imugene COO


Friday, 28 August, 2015

Immuno-oncology company Imugene (ASX:IMU) has appointed Leslie Chong as its new chief operating officer as of mid-September — a move which saw the company’s share price rise by 25% on Thursday.

Chong was most recently a senior clinical program leader at Genentech, a San Francisco-based biotech company with a strong oncology franchise. Her appointment to Imugene will see her relocate to Sydney within the month.

“We are delighted that someone of Leslie’s calibre, deep immuno-oncology experience, industry networks — and from one of the world’s most successful and prestigious drug developers — has agreed to join our team,” said Imugene Executive Chairman Paul Hopper. “IMU is at an important stage of its clinical development and Leslie’s deep, hands-on clinical trial experience across many studies will be invaluable to us.”

Imugene’s lead product is HER-Vaxx, a proprietary HER-2 positive cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian, lung and pancreatic cancers.

“Immuno-oncology is revolutionising the treatment of cancer, and I believe Imugene’s technology shows great promise,” said Chong. “The compelling science against the validated HER-2 target, a world-class drug development team in Dr Axel Hoos and Professor Ursula Weidermann, and the opportunity to build out additional pipeline with Imugene’s mimotope technology provides a very sound foundation for future success.”

Imugene has also announced that its managing director, Charles Walker, will be stepping down into the role of non-executive director with the company. Walker was thanked by Hopper for his leadership and contribution to Imugene — in particular for laying the groundwork for the company’s upcoming Phase 1b/2 trial of HER-Vaxx in patients with gastric cancer.

Imugene (ASX:IMU) shares were trading 25% higher at $0.010 as of around 3.30 pm on Thursday.

Related News

Microgravity causes changes in gene expression rhythms

Astronauts exposed to microgravity experience changes to physiology, including immune...

NSW, Qld announce RSV immunisation programs for infants

The government-funded programs have been designed to ensure infants and young children at the...

Gut bacteria appear important for overcoming milk allergy

Gut bacteria are thought to help reduce allergic reactions to some foods, but little is known...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd